Friday, July 10, 2026

Drug profile · INN

bictegravir, emtricitabine and tenofovir alafenamide

bictegravir, emtricitabine and tenofovir alafenamide (BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — bictegravir, emtricitabine and tenofovir alafenamide
US status
approved
Class
Route
Patents
0
Programs
0
Data quality
0.81

Quick answer

bictegravir, emtricitabine and tenofovir alafenamide (BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

Key facts

INN bictegravir, emtricitabine and tenofovir alafenamide
Brand BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is bictegravir, emtricitabine and tenofovir alafenamide?

bictegravir, emtricitabine and tenofovir alafenamide (BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

What is the brand name for bictegravir, emtricitabine and tenofovir alafenamide?

BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a marketed brand name for bictegravir, emtricitabine and tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of bictegravir, emtricitabine and tenofovir alafenamide?

bictegravir, emtricitabine and tenofovir alafenamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.